PL37 for the treatment of neuropathic pain (PL37-C03-2013)
A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabapentin.
EudraCT Number: 2013-004876-37
Status : Recruitment closed
PL265 Phase 1 Study (PL265-C01-2014)
Phase I, randomised, double-blind, placebo-controlled single oral dose escalation study to investigate the safety, tolerability and pharmacokinetics of PL265 in young healthy male volunteers.
EudraCT Number: 2014-000192-41
Status : Ongoing